I have the plan documents and the written criteria, which took two calls to obtain.
I understand the observation; what I do not understand is the mechanism behind it.
I have read the two review articles that come up first and both assert this without a citation to a primary source.
Can someone derive this rather than assert it?
The short version: legitimate under a prescription within defined limits, unapproved by definition, and quality depends entirely on the facility.
Beyond-use dates on compounded sterile preparations are set by standards that depend on the preparation environment and are much shorter than a manufactured product's shelf life.
| Line | Brand, insured | Compounded, subscription | Research-grade, self-tested |
|---|---|---|---|
| Product | Copay × 12 | Monthly fee × 12 | Vials × unit price |
| Consultation | Covered or copay | Bundled | Not applicable |
| Monitoring labs | Often covered | Usually not | Self-funded |
| Independent testing | Not applicable | Optional | Essential; per lot |
| Shipping | Pharmacy | Included | Per order |
| Dominant cost | Copay structure | Subscription fee | Testing |
Additives are the other divergence. Preparations combining an active with vitamins or other agents are not equivalent to the approved product and have not been studied in that combination.
Compounding is defined in regulation as preparation for an individual patient under prescription and is distinguished from manufacturing by scale and by the patient-specific requirement.
Check the beyond-use date and what it was based on.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsCopies of commercially available products are generally not permitted, which is the constraint that shapes most of this market.
Compounding is the preparation of a medicine for an individual patient in response to a prescription, where an approved product is unsuitable. It sits outside the approval framework by design rather than by omission.
Ask for the certificate of analysis on the compounded lot. A serious facility will have one; the request itself is informative.
Compounded means unapproved by definition. That is structural, not pejorative.
The relevant distinction is between compounding for an individual patient and compounding at scale, which are regulated differently.
Facility quality varies enormously and is the practical determinant of what you receive. The relevant questions are about sterility assurance, potency testing and beyond-use dating.
A compounded preparation has no marketing authorisation, no batch release by a qualified person and no pharmacovigilance obligation attached to it. That is the structural difference from a licensed product.
Regulatory warnings have specifically addressed salt forms differing from the approved active moiety in this therapeutic area.
A compounded preparation is unapproved by definition, which is a statement about the framework rather than about the facility.
Ask for the certificate of analysis on the lot. A serious facility has one.
Start with the regulatory basis, because compounding is permitted under specific conditions and those conditions are the whole subject.
Regulators generally prohibit compounding what is essentially a copy of a commercially available product, with a shortage listing being the usual exception that permits it temporarily.
Nothing here is medical advice.
The framework is jurisdiction-specific. Check yours rather than a general answer.
The honest answer is that a well-run compounding pharmacy is a serious operation and that the variance across facilities is wide.
Salt forms matter: a compounded preparation using a different salt from the approved product is not the same active moiety, and that has been the specific object of regulatory warnings.
Beyond-use dating for compounded sterile preparations is governed by published standards keyed to the compounding environment.
The caveat is that the legal and regulatory position differs by jurisdiction and nothing here is legal advice.
Ask which salt form. A different salt is a different active moiety.
edited 1 Oct 2024 by pierce_count — added the citation requested in comments
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.